MDGSW (Medigus) Stock Based Compensation: $0.38 Mil (TTM As of Dec. 2024)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MDGSW Medigus Ltd MDGSW
12 GF Score
Price $0.02
! 6 Warning Signs
View Full Analysis

What is Medigus Stock Based Compensation?

Medigus MDGSW 12 Stock Based Compensation is $0.38 Mil as of Dec. 2024. GuruFocus rates MDGSW with a GF Score™ of 12/100. The stock has 6 warning signs investors should review.

Medigus's Stock Based Compensation for the six months ended in Dec. 2024 was $0.19 Mil. Its Stock Based Compensation for the trailing twelve months (TTM) ended in Dec. 2024 was $0.38 Mil.

Medigus Stock Based Compensation Related Terms

Medigus Stock Based Compensation Historical Data

* Premium members only.

The historical data trend for Medigus's Stock Based Compensation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Medigus Stock Based Compensation Chart

Medigus Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Stock Based Compensation
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.39 2.36 0.79 1.02 0.38

Medigus Semi-Annual Data
Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Stock Based Compensation Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.16 0.47 0.55 0.19 0.19
MDGSW
12GF Score
Medigus Ltd MDGSW
Stock Based Compensation is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Medigus Stock Based Compensation Calculation

Stock Based Compensation is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.

Stock Based Compensation for the trailing twelve months (TTM) ended in Dec. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was $0.38 Mil.

What does a Stock Based Compensation of $0.38 Mil mean?
Medigus (MDGSW) has a Stock Based Compensation of $0.38 Mil as of Dec. 2024. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for Medigus and its competitors.
Is Medigus' Stock Based Compensation too high?
Medigus' current Stock Based Compensation is $0.38 Mil. Overall, Medigus has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Medigus' Stock Based Compensation compare to RMSL and HSDT?
Medigus' Stock Based Compensation of $0.38 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Stock Based Compensation for a Medical Devices & Instruments company?
A good Stock Based Compensation depends on the Medical Devices & Instruments industry context. However, Stock Based Compensation should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Stock Based Compensation mean?
A high Stock Based Compensation can signal that a stock is expensive relative to its fundamentals. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for Medigus and its competitors. Medigus's current Stock Based Compensation is $0.38 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medigus stock overvalued right now?
Medigus (MDGSW) has a current Stock Based Compensation of $0.38 Mil. The current Stock Based Compensation is $0.38 Mil. Medigus' overall GF Score™ is 12/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Stock Based Compensation calculated?
Stock Based Compensation is calculated from a company's financial statements. For Medigus (MDGSW), the current Stock Based Compensation is $0.38 Mil as of Dec. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Medigus Business Description

Address 10 Hanechoshet Street, 4th Floor, Tel Aviv, ISR, 6971072
Xylo Technologies Ltd is an Israel-based medical device company. The company is engaged in the development, manufacturing, and marketing of direct vision systems for minimally invasive medical procedures and safety systems for drones and the electric vehicle (EV) sector. The key product of the company is the MUSE (Medigus Ultrasonic Surgical Endostapler) system is a single-use device for the incision-less treatment of GERD (gastroesophageal reflux disease), which is based on proprietary platform technology and know-how. The company operates in four segments are: Corporate, Online advertising & internet traffic routing, Online event management, real-estate and electronics. The company's geographical segments include USA, Europe, Great Britain, Israel, Canada, Asia and others.
12GF Score

Get the complete analysis for MDGSW

Stock Based Compensation is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.02
Price